Dong-A ST stated that its R&D expertise has been reaffirmed by the positive CHMP opinion, following the FDA approval for ...
Imuldosa®, a biosimilar to Stelara®, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), paving the way for its authorization in Europe. Developed by Accord ...
J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and ...
The FDA has approved Imuldosa, a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.
Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...
Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...
Q3 2024 Earnings Call Transcript October 15, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.42, ...
GlobalData on MSN5d
Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’sStelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...
The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.
On Tuesday, Johnson & Johnson (NYSE: JNJ) posted better-than-expected third quarter sales and adjusted profit. Fueled by ...
The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback